RayKnowChina Research Map
Shortlist

RecruitingPancreatic cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial

An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by Zhongshan Hospital, Fudan University; 1 other hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
  2. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06946901, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Use of any non-anti-tumor investigational drugs within 4 weeks prior to treatment;

    Exclusion criterion 3

  3. No contraindications to surgery, with an ECOG performance status of 0-1;

    Inclusion criterion 3

  4. Hematological criteria: White blood cells (WBC) >=3.0 × 10⁹/L; Absolute neutrophil count (ANC) >=1.5 × 10⁹/L; Platelets (PLT) >=100 × 10⁹/L; Hemoglobin (Hgb) >=90 g/L.

    Inclusion criterion 7

    Blood biochemistry criteria: AST (SGOT) and ALT (SGPT) <=2.5 × upper limit of normal (ULN); Total bilirubin (TBIL) <=2 × ULN; Serum creatinine (CRE) <=1.5 × ULN.

    Inclusion criterion 8

    Coagulation function: Prothrombin time (PT) and international normalized ratio (INR) <=1.5 × ULN;

    Inclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06946901, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Obtain signed informed consent from the patient or their legal representative, with adherence to the study protocol and follow-up procedures;
  • Aged >=18 and <=80 years, regardless of gender;
  • No contraindications to surgery, with an ECOG performance status of 0-1;
  • Confirmed peritoneal metastasis by imaging or intraoperative detection, with rapid intraoperative histopathology indicating metastatic adenocarcinoma;
  • No prior anti-tumor therapy before treatment, including systemic chemotherapy, interventional chemotherapy, high-intensity focused ultrasound (HIFU), radiotherapy, immunotherapy, molecular targeted therapy, or traditional Chinese medicine anti-tumor treatments;
  • No severe hematological, cardiac, pulmonary dysfunction, or autoimmune deficiency (based on respective diagnostic criteria);
  • Hematological criteria: White blood cells (WBC) >=3.0 × 10⁹/L; Absolute neutrophil count (ANC) >=1.5 × 10⁹/L; Platelets (PLT) >=100 × 10⁹/L; Hemoglobin (Hgb) >=90 g/L.
  • Blood biochemistry criteria: AST (SGOT) and ALT (SGPT) <=2.5 × upper limit of normal (ULN); Total bilirubin (TBIL) <=2 × ULN; Serum creatinine (CRE) <=1.5 × ULN.
  • Coagulation function: Prothrombin time (PT) and international normalized ratio (INR) <=1.5 × ULN;
  • Compliance with study visit schedules and other protocol requirements.

Exclusion Criteria:

  • Presence of distant metastases to other organs (e.g., liver, bone, lung) with definitive evidence, except for ovarian metastases;
  • History of other systemic malignancies within the past five years;
  • Use of any non-anti-tumor investigational drugs within 4 weeks prior to treatment;
  • Accompanied by massive ascites (extending from pelvic to upper abdominal cavity);
  • History of upper gastrointestinal bleeding requiring repeated blood transfusions within the past three months;
  • Pregnancy, autoimmune diseases, severe hyperthyroidism/hypothyroidism, central nervous system disorders, psychiatric illnesses, unstable angina, congestive heart failure, severe arrhythmias, or other uncontrolled serious medical conditions;
  • History of hypersensitivity to the study drugs or medications with similar chemical structures;
  • Patients requiring long-term warfarin anticoagulation therapy;
  • Poor compliance, inability or unwillingness to provide signed informed consent;
  • Patients likely to be lost to follow-up for ≥14 days during the treatment period.

Quoted from ClinicalTrials.gov, NCT06946901, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06946901, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06946901